Tessa Therapeutics, a Temasek-backed clinical stage biotech company, is set to enter liquidation after failing to raise more funding for the development of its cancer treatment cell therapies or find a strategic buyer amid a market downturn, The Business Times reported citing the company’s letter to shareholders.
End the Year with a Deal You Can’t Miss!
Subscribe now and save 40% on our premium subscription.
Enjoy unlimited access for a full year at just $199 (usual price $339).
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Offer valid for a limited time – don’t wait to unlock the insights that drive deal-making in Asia!
Subscribe nowAlready a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
